Soligenix (SNGX) Posts Earnings Results, Hits Estimates
Soligenix (NASDAQ:SNGX) posted its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11), MarketWatch Earnings reports. Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. The business had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.40 million.
Shares of SNGX traded down $0.04 during midday trading on Friday, reaching $1.10. 140,125 shares of the stock were exchanged, compared to its average volume of 219,986. Soligenix has a 52 week low of $0.91 and a 52 week high of $3.70.
In other news, Director Mark E. Pearson purchased 170,000 shares of the company’s stock in a transaction dated Wednesday, October 17th. The shares were acquired at an average price of $1.16 per share, with a total value of $197,200.00. Following the transaction, the director now owns 2,500,000 shares of the company’s stock, valued at $2,900,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have bought a total of 182,230 shares of company stock worth $212,392 in the last three months. Corporate insiders own 5.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Soligenix (SNGX) Posts Earnings Results, Hits Estimates” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://theolympiareport.com/2018/11/10/soligenix-sngx-posts-earnings-results-hits-estimates.html.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Featured Story: What does EPS mean?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.